Current Good Manufacturing Practice (GMP) in the pharmaceutical and medical device industry is a Food and Drug Agency (FDA) mandated requirement to ensure all production activities are executed by trained operatives following approved documented procedures that utilize only fully validated and calibrated equipment, facilities and utilities. (21 CFR Part 820/210/211/11 Refers.)
FDA regulations use the phrase "current good manufacturing practice cgmp's" (GLP/GMP Validation) to describe these guidelines. Courts may theoretically hold that a drug product is adulterated even if there is no specific regulatory requirement that was violated as long as the process was not performed according to industry standards. By June 2010, the same GLP/GMP Validation requirements will apply to all manufacturers of dietary supplements. The World Health Organization (WHO) version of cGMP Validation is used by pharmaceutical regulators and the pharmaceutical industry in over one hundred countries worldwide, primarily in the developing world. The European Union's cGMP (EU-GMP) enforces similar requirements to WHO cGMP Validation, as does the Food and Drug Administration's version in the US. Similar current Good Manufacturing Practice based validations are used in other countries, with Australia, Canada, Japan, Singapore and others having highly developed/sophisticated current Good Manufacturing Practice requirements. In the United Kingdom, the Medicines Act (1968) covers most aspects of cGMP in what is commonly referred to as "The Orange Guide", which is named so because of the colour of its cover; it is officially known as Rules and Guidance for Pharma Manufacturers and Distributors.
Current Good Manufacturing Practice (for medicinal products) is that part of Quality Assurance which ensures that Medicinal products are consistently produced and controlled to the quality standards appropriate to their intended use and as required by the marketing authorization or product specification. Current Good manufacturing Practice continually concerned with both production and quality control.
Current Good Manufacturing Practice (cGMP), are issued by regulatory authorities throughout the world, country by country and region by region. In general they list minimum standards for the safe manufacture, storage and distribution of medicinal drugs, devices and all associated records. GMP rules and FDA regulations are just as enforceable (in the country of their origin) as is common criminal law. Because pharmaceutical products and their raw materials are manufactured and distributed internationally, collaborations between manufacturing companies has led to national authorities introducing commonality in many specifications and standards; this is a continuous and ongoing process.
There are several different sections to Current Good Manufacturing Practice validation requirements; as detailed in CFR’s, so it is essential to study those applicable to your processes. I.E. Medical Device, Biotech, Human Food, or Drugs. Manufacturers must adapt a very positive and proactive approach in conforming and enforcing the rules and guidelines throughout their entire manufacturing, inspecting, storing and distribution processes. They are required to implement processes and procedures that comply with the requirements listed in the applicable current Good Manufacturing Practices (cGMP) and gain approval from their regulatory authority that they comply with all of these regulations prior to being allowed to release their produce for public or prescribed use. They are subject to continuous monitoring of this regulated state.
Current Good Manufacturing Practice cGMP and FDA regulations have been developed to ensure that medicinal pharmaceutical products are consistently produced and controlled to the quality standards appropriate to their intended use. They have been developed and introduced in 1962 in response to the US public’s concern about the safety, efficacy and overall quality of drugs. In the United States the regulations are called cGMP to take into account that the regulations are not static but rather dynamic. They are defined in Title 21 of the U.S. Code of Federal Regulations: 21 CFR 210 – current good Manufacturing Practice for drugs in general and 21 CFR 211 – Current good Manufacturing Practice, for finished pharmaceuticals. In 1996 the FDA proposed a significant revision of the regulation. Any drug marketed in the US must first receive FDA approval, and must be manufactured in accordance with the US Current Good Manufacturing Practice regulations. Because of this, FDA regulations have set an international regulation benchmark for pharmaceutical manufacturing.
In Europe local current Good Manufacturing Practices cGMP, regulations exist in many countries. They are based on the European Union (EU) directive: Manufacturing Practice for Medicinal Products in the European Community. This EU GMP is necessary to permit free trade in medicinal products between the member countries. Regulations in the EU allow for the marketing of a new drug in the twelve member countries with a single marketing approval.
The EU GMP is intended to establish a minimum manufacturing standard for all member states. The EU directive has been widely harmonized with the Guide to current excellent Manufacturing Practice for Pharmaceutical Products as developed by the Pharmaceutical Inspection Convention (PIC).10
For Your Security We are Now TLS 1.2 Compliant
All you need to do is follow the prompts in the attached SOP. They will take you through the completion process section, by section. At the end of this process your generic document has progressed into a detailed, referenced, bespoke company document. The document follows our three level URS system that ensures functionality traceability from the URS to the various testing protocols. A great document to author and use. This document interfaces with our Validation Risk Assessment (VRA), Validation Project Plan (VP), User Requirements Specification (URS), giving a seamless flow from your VMP through the VP - IQ - OQ - PQ, while integrating flawlessly with the URS - DQ - VRA.
The Validation Plan (VP), is the starting point for any validation task, and the most important validation document. It improves validation efficiency greatly by forcing all concerned to document, review, and discuss, the proposed methods and allotted responsibilities. It is a mandated document with regulators and auditors.
While in the past validation was more focused on functions of procedures, recently the focus has progressed into infrastructure, networked systems and on security, authenticity and integrity of data acquired and evaluated by systems.
This document was designed to be used as a live document up until the DQ is completed and approved. It uses three levels of URS, URS Level 1, 2 and 3, and is the only URS to guarantee traceability from the URS through to the final PQ and OQ functionality testing. A mandatory requirement for Full Life Cycle Validation of computer systems that are the subject of predicate rules. It can be used on mechanical, electrical and software controlled, monitored or driven systems